MALVERN, Pa., March 11, 2025 /PRNewswire/ — Endo, Inc. (“Endo” or the “Company”) (OTCQX: NDOI) today announced it has entered into a definitive agreement to divest its International Pharmaceuticals business, primarily operated through Canada-based specialty pharmaceutical company Paladin…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.